Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Liabilities (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Total Liabilities data on record, last reported at $705.1 million in Q4 2025.

  • For Q4 2025, Total Liabilities rose 7.4% year-over-year to $705.1 million; the TTM value through Dec 2025 reached $705.1 million, up 7.4%, while the annual FY2025 figure was $705.1 million, 7.4% up from the prior year.
  • Total Liabilities reached $705.1 million in Q4 2025 per APLS's latest filing, up from $657.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $841.4 million in Q2 2021 and bottomed at $565.3 million in Q1 2024.
  • Average Total Liabilities over 5 years is $644.4 million, with a median of $649.8 million recorded in 2024.
  • Peak YoY movement for Total Liabilities: soared 76.41% in 2021, then fell 20.6% in 2022.
  • A 5-year view of Total Liabilities shows it stood at $683.1 million in 2021, then dropped by 13.58% to $590.3 million in 2022, then grew by 0.65% to $594.2 million in 2023, then rose by 10.49% to $656.5 million in 2024, then grew by 7.4% to $705.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $705.1 million in Q4 2025, $657.6 million in Q3 2025, and $665.1 million in Q2 2025.